Adamis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ADMP)

$3.20 +0.28 (+9.59 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$3.20
Today's Range$2.95 - $3.20
52-Week Range$2.81 - $6.45
Volume1.41 million shs
Average Volume638,470 shs
Market Capitalization$106.84 million
P/E RatioN/A
Dividend YieldN/A
Beta0.19

About Adamis Pharmaceuticals (NASDAQ:ADMP)

Adamis Pharmaceuticals logoAdamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Receive ADMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMP
CUSIPN/A
Phone858-997-2400

Debt

Debt-to-Equity Ratio0.06%
Current Ratio3.93%
Quick Ratio3.79%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.47 million
Price / Sales16.51
Cash FlowN/A
Price / CashN/A
Book Value$1.17 per share
Price / Book2.74

Profitability

Trailing EPSN/A
Net Income$-19,430,000.00
Net Margins-143.15%
Return on Equity-57.74%
Return on Assets-42.37%

Miscellaneous

Employees16
Outstanding Shares33,390,000

Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) posted its quarterly earnings data on Monday, November, 14th. The specialty pharmaceutical company reported ($0.41) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.48) by $0.07. The specialty pharmaceutical company earned $2.08 million during the quarter. Adamis Pharmaceuticals had a negative return on equity of 57.74% and a negative net margin of 143.15%. View Adamis Pharmaceuticals' Earnings History.

When will Adamis Pharmaceuticals make its next earnings announcement?

Adamis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 29th 2018. View Earnings Estimates for Adamis Pharmaceuticals.

Where is Adamis Pharmaceuticals' stock going? Where will Adamis Pharmaceuticals' stock price be in 2018?

3 analysts have issued 1-year target prices for Adamis Pharmaceuticals' stock. Their predictions range from $5.00 to $10.00. On average, they anticipate Adamis Pharmaceuticals' share price to reach $7.33 in the next twelve months. View Analyst Ratings for Adamis Pharmaceuticals.

What are Wall Street analysts saying about Adamis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Adamis Pharmaceuticals stock:

  • 1. Maxim Group analysts commented, "We have not had any recent news on the launch and other developments associated with Symjepi. As a result, we are increasing our therapeutics risk cut to 30%, from 25%, in our Epinephrine Pre-Filled syringe model, commercial assumptions. In addition, we are also pushing-out our timing back for the other" pipeline products models which include APC-1000, APC-2000 and APC-5000 inhalers. The result of these changes is our price target falls to $5, from $14." (2/14/2018)
  • 2. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (1/16/2018)

Who are some of Adamis Pharmaceuticals' key competitors?

Who are Adamis Pharmaceuticals' key executives?

Adamis Pharmaceuticals' management team includes the folowing people:

  • Richard C. Williams, Independent Chairman of the Board (Age 71)
  • Dennis J. Carlo Ph.D., President, Chief Executive Officer, Director (Age 71)
  • Robert O. Hopkins, Chief Financial Officer, Vice President - Finance (Age 54)
  • David J. Marguglio, Senior Vice President - Corporate Development, Director (Age 44)
  • Karen K. Daniels, Vice President - Operations (Age 62)
  • Gus Fernandez Pharm.D., Vice President - Commercial Operations (Age 54)
  • Thomas Moll Ph.D., Vice President - Research (Age 49)
  • William Charles Denby III, Independent Director (Age 60)
  • Robert B. Rothermel, Independent Director (Age 71)

Who owns Adamis Pharmaceuticals stock?

Adamis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include B. Riley Financial Inc. (0.70%), Virtu Financial LLC (0.30%) and Wells Fargo & Company MN (0.08%). View Institutional Ownership Trends for Adamis Pharmaceuticals.

Who bought Adamis Pharmaceuticals stock? Who is buying Adamis Pharmaceuticals stock?

Adamis Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including B. Riley Financial Inc., Virtu Financial LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Adamis Pharmaceuticals.

How do I buy Adamis Pharmaceuticals stock?

Shares of Adamis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamis Pharmaceuticals' stock price today?

One share of Adamis Pharmaceuticals stock can currently be purchased for approximately $3.20.

How big of a company is Adamis Pharmaceuticals?

Adamis Pharmaceuticals has a market capitalization of $106.84 million and generates $6.47 million in revenue each year. Adamis Pharmaceuticals employs 16 workers across the globe.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]


MarketBeat Community Rating for Adamis Pharmaceuticals (ADMP)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  237
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Adamis Pharmaceuticals (NASDAQ:ADMP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.33$10.33$10.00$9.00
Price Target Upside: 103.70% upside158.33% upside115.05% upside95.65% upside

Adamis Pharmaceuticals (NASDAQ:ADMP) Consensus Price Target History

Price Target History for Adamis Pharmaceuticals (NASDAQ:ADMP)

Adamis Pharmaceuticals (NASDAQ:ADMP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018Maxim GroupSet Price TargetBuy$5.00LowView Rating Details
11/30/2017B. RileySet Price TargetBuy$10.00MediumView Rating Details
9/12/2017Raymond James FinancialInitiated CoverageOutperform$7.00HighView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Adamis Pharmaceuticals (NASDAQ:ADMP) Earnings History and Estimates Chart

Earnings by Quarter for Adamis Pharmaceuticals (NASDAQ:ADMP)

Adamis Pharmaceuticals (NASDAQ ADMP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018        
8/14/2017Q2 2017($0.19)$3.81 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.21)($0.26)$3.00 million$3.04 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.48)($0.41)$2.08 millionViewN/AView Earnings Details
8/15/2016Q2($0.37)$1.93 millionViewN/AView Earnings Details
5/13/2016Q1 2016($0.48)ViewN/AView Earnings Details
3/23/2016Q4 2015($0.21)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.24)ViewN/AView Earnings Details
8/7/2015Q2 2015($0.27)ViewN/AView Earnings Details
5/14/2015Q1 2015($0.32)ViewN/AView Earnings Details
11/14/2014Q3 2014($0.20)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.27)ViewN/AView Earnings Details
6/23/2014Q1 2014($0.18)ViewN/AView Earnings Details
2/14/2014Q4 2013($0.82)ViewN/AView Earnings Details
11/13/2013Q3 2013($0.17)ViewN/AView Earnings Details
8/19/2013Q2 2013($2.89)ViewN/AView Earnings Details
2/14/2012Q4 2011($0.19)ViewN/AView Earnings Details
11/21/2011Q3 2011($0.27)ViewN/AView Earnings Details
5/13/2009Q4 2008($0.19)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Adamis Pharmaceuticals (NASDAQ:ADMP) Earnings Estimates

2018 EPS Consensus Estimate: ($0.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.14)($0.14)($0.14)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.17)($0.17)($0.17)
Q4 20181($0.16)($0.16)($0.16)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Adamis Pharmaceuticals (NASDAQ:ADMP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Adamis Pharmaceuticals (NASDAQ ADMP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 16.70%
Insider Trades by Quarter for Adamis Pharmaceuticals (NASDAQ:ADMP)
Institutional Ownership by Quarter for Adamis Pharmaceuticals (NASDAQ:ADMP)

Adamis Pharmaceuticals (NASDAQ ADMP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/2/2016David J MarguglioVPSell700$9.00$6,300.00101,527View SEC Filing  
5/16/2016David J MarguglioSVPSell4,000$8.08$32,320.00102,227View SEC Filing  
5/9/2016David J MarguglioSVPSell4,860$10.00$48,600.00106,227View SEC Filing  
5/4/2016David J MarguglioSVPSell4,860$9.17$44,566.20112,227View SEC Filing  
5/3/2016David J MarguglioSVPSell1,140$9.00$10,260.00117,087View SEC Filing  
4/14/2016David J MarguglioSVPSell12,000$7.52$90,240.00118,227View SEC Filing  
8/14/2015Robert B RothermelDirectorBuy7,000$3.33$23,310.00View SEC Filing  
4/20/2015David J MarguglioSVPSell200$5.00$1,000.00View SEC Filing  
4/14/2015David J MarguglioSVPSell2,200$5.01$11,022.00View SEC Filing  
3/4/2015David J MarguglioSVPSell11,800$7.09$83,662.00View SEC Filing  
3/2/2015David J MarguglioSVPSell7,000$6.45$45,150.00View SEC Filing  
2/13/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell12,076$6.41$77,407.16View SEC Filing  
2/12/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell38,000$6.40$243,200.00View SEC Filing  
2/3/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell30,000$6.75$202,500.00View SEC Filing  
1/5/2015David J MarguglioVPSell7,000$6.18$43,260.00View SEC Filing  
12/30/2014David J MarguglioSVPSell12,228$6.09$74,468.52View SEC Filing  
12/29/2014David J MarguglioVPSell772$6.00$4,632.00View SEC Filing  
12/12/2014David J MarguglioSVPSell4,000$5.18$20,720.00View SEC Filing  
9/2/2014William C DenbyDirectorBuy2,500$5.06$12,650.00View SEC Filing  
8/29/2014Robert B RothermelDirectorBuy5,500$4.03$22,165.00View SEC Filing  
6/2/2014David J MarguglioSVPSell4,000$5.56$22,240.00View SEC Filing  
8/14/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell7,015$0.57$3,998.55View SEC Filing  
8/7/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell40,000$0.56$22,400.00View SEC Filing  
8/2/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell67,960$0.57$38,737.20View SEC Filing  
7/30/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell10,328$0.56$5,783.68View SEC Filing  
7/26/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell95,000$0.56$53,200.00View SEC Filing  
7/23/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell141,224$0.57$80,497.68View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Adamis Pharmaceuticals (NASDAQ ADMP) News Headlines

Source:
DateHeadline
What Happened To Adamis? - Seeking AlphaWhat Happened To Adamis? - Seeking Alpha
seekingalpha.com - February 18 at 8:33 AM
Adamis Pharmaceuticals (ADMP) Given a $5.00 Price Target at Maxim GroupAdamis Pharmaceuticals (ADMP) Given a $5.00 Price Target at Maxim Group
www.americanbankingnews.com - February 14 at 1:38 PM
Adamis Pharmaceuticals Announces FDA Acceptance for Review for the Supplemental New Drug Application of Its ... - GlobeNewswire (press release)Adamis Pharmaceuticals Announces FDA Acceptance for Review for the Supplemental New Drug Application of Its ... - GlobeNewswire (press release)
globenewswire.com - February 14 at 6:37 AM
Zacks: Analysts Anticipate Adamis Pharmaceuticals Corp (ADMP) Will Post Earnings of -$0.15 Per ShareZacks: Analysts Anticipate Adamis Pharmaceuticals Corp (ADMP) Will Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - February 14 at 5:24 AM
Adamis Pharmaceuticals Announces FDA Acceptance for Review for the  Supplemental New Drug Application of Its Low Dose Symjepi Product CandidateAdamis Pharmaceuticals Announces FDA Acceptance for Review for the  Supplemental New Drug Application of Its Low Dose Symjepi Product Candidate
finance.yahoo.com - February 12 at 3:25 PM
Critical Review: Adamis Pharmaceuticals (ADMP) versus Amgen (AMGN)Critical Review: Adamis Pharmaceuticals (ADMP) versus Amgen (AMGN)
www.americanbankingnews.com - February 7 at 1:12 AM
Novartis (NVS) & Adamis Pharmaceuticals (ADMP) Head-To-Head SurveyNovartis (NVS) & Adamis Pharmaceuticals (ADMP) Head-To-Head Survey
www.americanbankingnews.com - February 6 at 11:06 PM
Zacks: Analysts Set $10.17 Price Target for Adamis Pharmaceuticals Corp (ADMP)Zacks: Analysts Set $10.17 Price Target for Adamis Pharmaceuticals Corp (ADMP)
www.americanbankingnews.com - February 3 at 3:22 PM
$4.05 Million in Sales Expected for Adamis Pharmaceuticals Corp (ADMP) This Quarter$4.05 Million in Sales Expected for Adamis Pharmaceuticals Corp (ADMP) This Quarter
www.americanbankingnews.com - January 30 at 6:54 AM
Adamis Pharmaceuticals: January Thesis Update - Seeking AlphaAdamis Pharmaceuticals: January Thesis Update - Seeking Alpha
seekingalpha.com - January 25 at 3:25 PM
Contrasting Adamis Pharmaceuticals (ADMP) and Impax Laboratories (IPXL)Contrasting Adamis Pharmaceuticals (ADMP) and Impax Laboratories (IPXL)
www.americanbankingnews.com - January 22 at 8:26 AM
Adamis Pharmaceuticals (ADMP) Upgraded by Zacks Investment Research to HoldAdamis Pharmaceuticals (ADMP) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - January 16 at 5:24 PM
 Adamis Pharmaceuticals Corp (ADMP) Given $10.17 Consensus Target Price by Analysts Adamis Pharmaceuticals Corp (ADMP) Given $10.17 Consensus Target Price by Analysts
www.americanbankingnews.com - January 13 at 5:06 PM
 Analysts Anticipate Adamis Pharmaceuticals Corp (ADMP) Will Post Quarterly Sales of $4.05 Million Analysts Anticipate Adamis Pharmaceuticals Corp (ADMP) Will Post Quarterly Sales of $4.05 Million
www.americanbankingnews.com - January 13 at 2:00 PM
Adamis Pharmaceuticals Corp (ADMP) Expected to Announce Earnings of -$0.15 Per ShareAdamis Pharmaceuticals Corp (ADMP) Expected to Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - January 11 at 5:34 AM
Reviewing Eli Lilly and (LLY) & Adamis Pharmaceuticals (ADMP)Reviewing Eli Lilly and (LLY) & Adamis Pharmaceuticals (ADMP)
www.americanbankingnews.com - January 10 at 5:30 PM
Adamis Pharmaceuticals (ADMP) Cut to "Sell" at ValuEngineAdamis Pharmaceuticals (ADMP) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - December 31 at 12:46 AM
ETFs with exposure to Adamis Pharmaceuticals Corp. : December 26, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : December 26, 2017
finance.yahoo.com - December 26 at 12:46 PM
Can Adamis Bleed Mylan Dry? - Seeking AlphaCan Adamis Bleed Mylan Dry? - Seeking Alpha
seekingalpha.com - December 14 at 10:54 AM
ETFs with exposure to Adamis Pharmaceuticals Corp. : December 13, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : December 13, 2017
finance.yahoo.com - December 13 at 3:33 PM
US Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in HorsesUS Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in Horses
finance.yahoo.com - December 7 at 11:01 AM
Raymond James Sings the Praises of Adamis Pharmaceuticals; Here’s WhyRaymond James Sings the Praises of Adamis Pharmaceuticals; Here’s Why
finance.yahoo.com - December 6 at 11:46 AM
Adamis Pharmaceuticals (ADMP) PT Set at $14.00 by Maxim GroupAdamis Pharmaceuticals (ADMP) PT Set at $14.00 by Maxim Group
www.americanbankingnews.com - December 5 at 3:20 PM
Watch These December Biotech Catalysts - Seeking AlphaWatch These December Biotech Catalysts - Seeking Alpha
seekingalpha.com - December 5 at 11:28 AM
Adamis Pharmaceuticals Corp (ADMP) Moves Forward with a New Opioid Overdose DrugAdamis Pharmaceuticals Corp (ADMP) Moves Forward with a New Opioid Overdose Drug
finance.yahoo.com - December 5 at 11:28 AM
Adamis Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to the FDA for New Product Candidate for the Treatment of Opioid OverdoseAdamis Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to the FDA for New Product Candidate for the Treatment of Opioid Overdose
finance.yahoo.com - December 5 at 11:28 AM
 Adamis Pharmaceuticals Corp (ADMP) Given $9.83 Average Target Price by Analysts Adamis Pharmaceuticals Corp (ADMP) Given $9.83 Average Target Price by Analysts
www.americanbankingnews.com - December 5 at 11:26 AM
Adamis Pharmaceuticals (ADMP) vs. Its Peers Head to Head ReviewAdamis Pharmaceuticals (ADMP) vs. Its Peers Head to Head Review
www.americanbankingnews.com - December 2 at 1:06 PM
Adamis Pharmaceuticals Corp. :ADMP-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017Adamis Pharmaceuticals Corp. :ADMP-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 3:47 PM
This Bull Cheers for Adamis Pharmaceuticals Following PAS Submission for Pediatric Version of Epinephrine Auto-Injector SymjepiThis Bull Cheers for Adamis Pharmaceuticals Following PAS Submission for Pediatric Version of Epinephrine Auto-Injector Symjepi
finance.yahoo.com - December 1 at 3:47 PM
Adamis Pharmaceuticals Announces Presentation of Results of a Human Factors Study Conducted With Its Newly Approved Epinephrine Pre-filled Syringe at the American Academy of Allergy, Asthma and Immunology (AAAAI) Joint Congress With the World Allergy OrganizationAdamis Pharmaceuticals Announces Presentation of Results of a Human Factors Study Conducted With Its Newly Approved Epinephrine Pre-filled Syringe at the American Academy of Allergy, Asthma and Immunology (AAAAI) Joint Congress With the World Allergy Organization
finance.yahoo.com - December 1 at 3:47 PM
ETFs with exposure to Adamis Pharmaceuticals Corp. : November 30, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : November 30, 2017
finance.yahoo.com - November 30 at 3:32 PM
B. Riley Analysts Give Adamis Pharmaceuticals (ADMP) a $10.00 Price TargetB. Riley Analysts Give Adamis Pharmaceuticals (ADMP) a $10.00 Price Target
www.americanbankingnews.com - November 30 at 12:00 PM
Adamis Pharmaceuticals (ADMP) Gains After Submitting Prior Approval Supplement for Pediatric SymjepiAdamis Pharmaceuticals (ADMP) Gains After Submitting Prior Approval Supplement for Pediatric Symjepi
www.streetinsider.com - November 30 at 11:19 AM
Adamis Pharmaceuticals Submits Prior Approval Supplement to FDA for the Pediatric Version of SymjepiAdamis Pharmaceuticals Submits Prior Approval Supplement to FDA for the Pediatric Version of Symjepi
finance.yahoo.com - November 30 at 11:19 AM
Comparing Histogenics Corporation (HSGX) & Adamis Pharmaceuticals Corporation (ADMP)Comparing Histogenics Corporation (HSGX) & Adamis Pharmaceuticals Corporation (ADMP)
www.americanbankingnews.com - November 21 at 5:12 AM
Adamis Pharmaceuticals Corporation (ADMP) Stock Rating Lowered by Zacks Investment ResearchAdamis Pharmaceuticals Corporation (ADMP) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - November 21 at 12:52 AM
ETFs with exposure to Adamis Pharmaceuticals Corp. : November 20, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : November 20, 2017
finance.yahoo.com - November 20 at 5:01 PM
B. Riley Analysts Give Adamis Pharmaceuticals Corporation (ADMP) a $10.00 Price TargetB. Riley Analysts Give Adamis Pharmaceuticals Corporation (ADMP) a $10.00 Price Target
www.americanbankingnews.com - November 19 at 10:58 PM
Adamis Pharmaceuticals Corporation Expected to Earn FY2017 Earnings of ($0.78) Per Share (ADMP)Adamis Pharmaceuticals Corporation Expected to Earn FY2017 Earnings of ($0.78) Per Share (ADMP)
www.americanbankingnews.com - November 17 at 8:00 AM
Relative Strength Alert For Adamis PharmaceuticalsRelative Strength Alert For Adamis Pharmaceuticals
www.thestreet.com - November 16 at 10:46 AM
 Adamis Pharmaceuticals Corporation (ADMP) Given $9.83 Average Target Price by Brokerages Adamis Pharmaceuticals Corporation (ADMP) Given $9.83 Average Target Price by Brokerages
www.americanbankingnews.com - November 14 at 1:50 AM
ETFs with exposure to Adamis Pharmaceuticals Corp. : November 9, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : November 9, 2017
finance.yahoo.com - November 9 at 4:25 PM
Financial Analysis: Adamis Pharmaceuticals Corporation (ADMP) & The CompetitionFinancial Analysis: Adamis Pharmaceuticals Corporation (ADMP) & The Competition
www.americanbankingnews.com - November 7 at 10:59 AM
ETFs with exposure to Adamis Pharmaceuticals Corp. : October 30, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : October 30, 2017
finance.yahoo.com - October 30 at 3:41 PM
Adamis Pharmaceuticals: Limited Risk, But Skeptical About Gains ... - Seeking AlphaAdamis Pharmaceuticals: Limited Risk, But Skeptical About Gains ... - Seeking Alpha
seekingalpha.com - October 28 at 3:41 AM
First Week Of ADMP June 2018 Options TradingFirst Week Of ADMP June 2018 Options Trading
www.thestreet.com - October 26 at 11:31 AM
Adamis Pharmaceuticals: A Rocket Counting Down To Lift-Off - Seeking AlphaAdamis Pharmaceuticals: A Rocket Counting Down To Lift-Off - Seeking Alpha
seekingalpha.com - October 25 at 4:16 PM
Adamis Pharmaceuticals: A ~$5 Biotech Stock That Should Sell For $10Adamis Pharmaceuticals: A ~$5 Biotech Stock That Should Sell For $10
seekingalpha.com - October 20 at 3:41 PM
ETFs with exposure to Adamis Pharmaceuticals Corp. : October 20, 2017ETFs with exposure to Adamis Pharmaceuticals Corp. : October 20, 2017
finance.yahoo.com - October 20 at 3:40 PM

SEC Filings

Adamis Pharmaceuticals (NASDAQ:ADMP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Adamis Pharmaceuticals (NASDAQ:ADMP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Adamis Pharmaceuticals (NASDAQ ADMP) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.